Metabolic Diseases
Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
Subtype terms (19)
More specific conditions that are subtypes of Metabolic Diseases in the MeSH hierarchy.
- Acid-Base Imbalance
8 drugs (6 approved, 2 experimental)
- Bone Diseases, Metabolic
99 drugs (55 approved, 44 experimental)
- Brain Diseases, Metabolic
1 drug experimental
- Calcium Metabolism Disorders
6 drugs approved
- DNA Repair-Deficiency Disorders
23 drugs (20 approved, 3 experimental)
- Glucose Metabolism Disorders
94 drugs (48 approved, 46 experimental)
- Hyperlactatemia
11 drugs approved
- Iron Metabolism Disorders
11 drugs (8 approved, 3 experimental)
- Lipid Metabolism Disorders
56 drugs (26 approved, 30 experimental)
- Malabsorption Syndromes
33 drugs (14 approved, 19 experimental)
- Metabolic Syndrome
395 drugs (148 approved, 247 experimental)
- Metabolism, Inborn Errors
28 drugs (14 approved, 14 experimental)
- Mitochondrial Diseases
61 drugs (37 approved, 24 experimental)
- Phosphorus Metabolism Disorders
1 drug approved
- Porphyrias
12 drugs (9 approved, 3 experimental)
- Proteostasis Deficiencies
1 drug approved
- Skin Diseases, Metabolic
- Wasting Syndrome
7 drugs (6 approved, 1 experimental)
- Water-Electrolyte Imbalance
6 drugs (5 approved, 1 experimental)
Drugs by status
Approved for this indication (4)
Phase 4 trials (24)
Phase 3 trials (30)
- vitamin d3
- heparin
- acetazolamide
- dulaglutide
- hydrocortisone
- icosapent ethyl
- in111-octreoscan
- soybean oil
- prolycopene
- meglitinides
- mipomersen
- vitamin c
- linagliptin
- conjugated linoleic acid
- thiamine
- ald-101
- losartan
- pioglitazone
- hydrochlorothiazide
- sufonylurea
- dapagliflozin
- sodium chloride
- glucose monohydrate
- lerodalcibep
- gnr-055
- ntla-2001
- obicetrapib
- biguanide
- rhgad65
- enavogliflozin
Phase 2 trials (60)
- orlistat
- allogeneic pancreatic islet cells
- anti cd45 monoclonal antibody
- acetylcysteine
- urea
- busulfan
- cat 2003
- clofarabine
- daclizumab
- deferitazole
- deferasirox
- ferrous fumarate
- tacrolimus
- haploidentical mononuclear cells
- hsc835
- hydroxyurea
- niacin
- acyline
- colchicine
- valsartan
- puerarin
- celecoxib
- sgs-742
- sirolimus
- cyclosporine
- mycophenolate
- rotigotine
- cyclophosphamide
- stem cells
- taurine
- +30 more
Phase 1 trials (29)
- melatonin
- bms-986036
- bpx-501
- bococizumab
- rosuvastatin
- hydrogen
- kisspeptin
- pf-04856883
- abiraterone
- carvedilol
- human fecal microbiota
- evinacumab
- human hepatocytes
- nexvax2
- bacillus subtilis
- prohema-cb
- amino acids
- avocado
- pxl770
- elafibranor
- avocadyne
- avocadene
- ckd-387
- d484
- azd2693
- christensenella minuta
- vctx210a
- amg 513
- nnc6022-0001
Other trials (100)
- ringer's lactate
- maltodextrin
- sodium nitrate
- sucrose
- phentermine
- olbetam
- vitamin e
- ammonia
- calcium carbonate
- astaxanthin
- beetroot juice
- betaine
- chromium tripicolinate
- exenatide
- cranberry
- dark chocolate
- deoxycytidine
- prednisone
- e. coli endotoxin
- egg
- empagliflozin
- vitis vinifera
- cannabidiol
- essential oils
- fiber
- folic acid
- somatropin
- glucagon like peptide-2
- l-glutamine
- glycine
- +70 more
Organizations
Organization Involved with Phase 4 Indications (46)
- Gilead Sciences
- Novartis
- Bayer
- Dong-A Pharmaceutical
- Panion & BF Biotech Inc.
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute on Aging (NIA)
- Maastricht University
- Central South University
- Baskent University
- Cornell University
- Garvan Institute of Medical Research
- Mahidol University
- McGill University
- McMaster University
- Osaka University
- Palacky University
- Policlinique Médicale Universitaire
- University of Lausanne
- University of Pisa
- University of Leipzig
- Laval University
- South East Asia Infectious Disease Clinical Research Network
- Taipei Medical University
- University of Calgary
- University of California, Los Angeles
- University of Naples Frederico II
- Medical University of Vienna
- University of Oxford
- +16 more
Organization Involved with Phase 3 Indications (26)
- Aventis
- Genzyme
- Pfizer
- Wyeth
- Aldagen
- Baxalta
- GlaxoSmithKline
- InfaCare Pharmaceuticals Corporation
- Ionis Pharmaceuticals, Inc.
- Kastle Therapeutics, LLC
- Kobe University
- Omicron Pharmaceuticals
- Solvay
- Duke University
- Emory University
- Translational Research Informatics Center, Kobe, Hyogo, Japan
- University of Alberta
- Tel Aviv University
- University of Colorado, Denver
- Isfahan University
- Hebrew University
- University of Turin
- Rafik Hariri University
- University of Colorado
- Heart and Stroke Foundation of Canada
- Canadian Institutes of Health Research (CIHR)
Organization Involved with Phase 2 Indications (70)
- Shire
- Roche
- Sanofi
- Diamyd
- Hamad Medical Corporation
- Longeveron LLC
- Spark Therapeutics
- Constant Pharmaceuticals
- Stem Cells Arabia
- National Human Genome Research Institute (NHGRI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Neurological Disorders and Stroke (NINDS)
- World Health Organization
- Aarhus University
- University of Pittsburgh
- Ain Shams University
- Alborz Medical University
- Augusta University
- Baylor University
- Cairo University
- Case Western Reserve University
- University of London
- University of Washington
- Institut National de la Santé Et de la Recherche Médicale, France
- Instituto Mexicano del Seguro Social
- Johns Hopkins University
- Stanford University
- University of Glasgow
- University of Groningen
- +40 more
Organization Involved with Phase 1 Indications (23)
- Regeneron
- AstraZeneca
- Bellicum Pharmaceuticals
- Fate Therapeutics
- ImmusanT, Inc.
- Parexel
- Poxel SA
- Pharmacosmos
- Genfit
- University of Illinois
- Medical College of Wisconsin
- Pavol Jozef Safarik University
- University of Guelph
- University of Rochester
- Renal Research Institute
- SGS Life Sciences
- Luye Pharma
- Naturalpha
- Ultragenyx Inc.
- The Marcus Foundation
- Ysopia Bioscience
- Women and Children's Health Research Institute (WCHRI)
- AO GENERIUM
Organization Involved with Other Experimental Indications (90)
- Takeda
- Unilever
- Aromtech Ltd.
- Atrium Innovations
- Biocinese
- Indena S.p.A
- Vital Solutions
- National Center for Complementary and Integrative Health (NCCIH)
- Slovak Academy of Sciences
- Swiss Federal Institute of Technology
- University of Roma La Sapienza
- Barmherzige Brüder Vienna
- IRCCS Burlo Garofolo
- University of Pennsylvania
- Medical University of Graz
- Centre National d'Etudes Spatiales
- Chang Gung University
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- DLR German Aerospace Center
- Federal University of Health Science of Porto Alegre
- Federal University of Rio Grande do Sul
- German Institute of Human Nutrition
- Instituto Venezolano de Investigaciones Cientificas
- Monash University
- Northumbria University
- Singapore General Hospital
- Translational Research Institute for Metabolism and Diabetes, Florida
- Universidade Estadual de Londrina
- Thomas Jefferson University
- University of Guadalajara
- +60 more